Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of August 2015. The report discloses a specific transaction involving an executive officer's acquisition of company securities, originally published on the Tel-Aviv Stock Exchange on June 25, 2015, with the transaction date occurring on August 16, 2015.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data point disclosed is the quoted price of the securities involved in the transaction:
- Security Type: Tradable Options (series 3)
- Quoted Price: 8 Agorot (NIS 0.08)
Material Changes
The material change reported is an increase in holdings by Uri Ben Or, an Executive Officer (not CEO or director). The specific details are:
- Transaction: Purchase of 10 Tradable Options (series 3).
- Date of Change: August 16, 2015.
- Previous Balance: 0 securities (0% holding).
- Current Balance: 10 securities (0% holding).
- Impact on Control: No change in equity or voting power (remains at 0%).
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a disclosure of a change in beneficial ownership.
Investor Verification Points
- Verify the total number of outstanding Tradable Options (series 3) to assess the significance of the 10-option purchase.
- Confirm the terms and expiration date of the "series 3" options to understand their potential value.
- Check subsequent filings to see if Uri Ben Or's holdings have increased further or if other insiders have made similar purchases.
- Note the discrepancy between the request metadata (Scinai Immunotherapeutics) and the filing content (BiondVax Pharmaceuticals).